EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Acute and chronic migraine treatment from standard therapies to new therapeutic options: A review of current knowledge (2019–2025)

Anna Dargacz, Agnieszka Siwiec, Maria Morawska, Alicja Ożga, Diana Szczepańska, Julia Kozikowska, Klaudia Szymczyk, Maciej Jakubik, Marta Kiżewska, Marta Owczarzak, Aleksandra Gajos, Zuzanna Wójcik

Humanities & Social Sciences Reviews · 24.05.2026 · 14 (1) · 124-132

DOI: 10.18510/hssr.2026.14115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Humanities & Social Sciences Reviews, online erschienen am 24.05.2026. Verfasst von Anna Dargacz und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Research objective: Migraine is a neurological disorder that significantly reduces patients' quality of life, social functioning, and professional productivity. The aim of this review is to present current treatment options for both acute migraine attacks and chronic migraine prevention, with particular focus on advances recorded between 2019 and 2025. Methodology: A narrative review of current knowledge was conducted, encompassing randomized clinical trials, meta-analyses, and clinical guidelines published between 2019 and 2025 concerning pharmacological and non-pharmacological treatment of acute and chronic migraine. Main conclusions: In the treatment of acute migraine attacks, NSAIDs remain the basis of therapy for mild to moderate episodes, while triptans are recommended for moderate to severe attacks. New drug classes — gepants (rimegepant, ubrogepant, zavegepant) and ditans (lasmiditan) — provide effective alternatives. Monoclonal anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and oral CGRP receptor antagonists have been shown to significantly reduce the number of migraine days and improve quality of life. OnabotulinumtoxinA remains an effective preventive treatment for chronic migraine. Application of the study: The findings support clinicians in selecting individualized treatment strategies for migraine patients by providing a comprehensive and up-to-date overview of available pharmacological and neuromodulation options, taking into account disease severity, comorbidities, and cost-availability factors. Originality/Novelty of the study: The review integrates evidence from the most recent clinical trials and meta-analyses (2019–2025), highlighting the paradigm shift in migraine management brought about by targeted CGRP-based therapies and non-invasive neuromodulation methods, enabling more personalized and effective patient care.

Zitieren

APA

Dargacz, A., Siwiec, A., Morawska, M., Ożga, A., Szczepańska, D., Kozikowska, J., Szymczyk, K., Jakubik, M., Kiżewska, M., Owczarzak, M., Gajos, A., & Wójcik, Z. (2026). Acute and chronic migraine treatment from standard therapies to new therapeutic options: A review of current knowledge (2019–2025). Humanities & Social Sciences Reviews, 14(1), 124-132. https://doi.org/10.18510/hssr.2026.14115

Vancouver

Dargacz A, Siwiec A, Morawska M, Ożga A, Szczepańska D, Kozikowska J, et al. Acute and chronic migraine treatment from standard therapies to new therapeutic options: A review of current knowledge (2019–2025). Humanities & Social Sciences Reviews. 2026;14(1):124-132. doi:10.18510/hssr.2026.14115

BibTeX
@article{Dargacz2026,
  author = {Dargacz, Anna and Siwiec, Agnieszka and Morawska, Maria and Ożga, Alicja and Szczepańska, Diana and Kozikowska, Julia and Szymczyk, Klaudia and Jakubik, Maciej and Kiżewska, Marta and Owczarzak, Marta and Gajos, Aleksandra and Wójcik, Zuzanna},
  title = {Acute and chronic migraine treatment from standard therapies to new therapeutic options: A review of current knowledge (2019–2025)},
  journal = {Humanities & Social Sciences Reviews},
  year = {2026},
  volume = {14},
  number = {1},
  pages = {124--132},
  doi = {10.18510/hssr.2026.14115}
}
Kostenlos starten →